



News Release

Cougar Biotechnology to Present at Cowen and Company 28th Annual Health Care Conference

Los Angeles, CA, March 11, 2008 – Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Cowen and Company 28th Annual Health Care Conference on Tuesday, March 18, at 4:40 p.m. EDT at The Boston Marriott Copley Place Hotel. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.

Interested investors may access a live audio webcast and accompanying slide presentation by visiting the Investor Relations section of the Company's Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17alpha-hydroxylase/c17,20 lyase enzyme, which is currently being tested in Phase II clinical trials in prostate cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.

Contacts:

Cougar Biotechnology, Inc., +1-310-943-8040

Alan H. Auerbach, Chief Executive Officer and President

ahauerbach@cougarbiotechnology.com

Mariann Ohanesian, Director of Investor Relations

mohanesian@cougarbiotechnology.com

Russo Partners, LLC

David Schull, +1-212-845-4271

David.schull@russopartnersllc.com

Timothy Engel, +1-212-845-4242

Timothy.engel@russopartnersllc.com

###